Kirsi Talala
Overview
Explore the profile of Kirsi Talala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
593
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pylvalainen J, Talala K, Raitanen J, Rannikko A, Auvinen A
BJU Int
. 2025 Jan;
PMID: 39840544
Objective: To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy. Patients And Methods: This...
2.
Ola I, Talala K, Tammela T, Taari K, Murtola T, Kujala P, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39643505
Background And Objective: Despite the evidence for prostate-specific antigen (PSA) screening reducing prostate cancer (PCa) mortality, the optimal PSA cutoff and the clinical significance of low initial PSA levels in...
3.
Pasanen N, Talala K, Remmers S, Tammela T, Hugosson J, Roobol M, et al.
BJU Int
. 2024 May;
134(2):291-299.
PMID: 38725182
Objective: To evaluate whether a subgroup of men can be identified that would benefit more from screening than others. Materials And Methods: This retrospective cohort study was based on three...
4.
Talala K, Walter S, Taari K, Tammela T, Kujala P, Auvinen A
Cancer Causes Control
. 2023 Dec;
35(4):695-703.
PMID: 38063980
Purpose: We assessed the risk of death from prostate cancer (PCa) in relation to men's screening histories, i.e., screening attendance among men who were offered screening. Methods: Men in the...
5.
Siltari A, Murtola T, Kausz J, Talala K, Taari K, Tammela T, et al.
Acta Oncol
. 2023 Nov;
62(12):1898-1904.
PMID: 37971326
Background: Concerns have been expressed over the safety of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH). Previous studies have shown controversial results regarding the association of TRT...
6.
Nygard L, Talala K, Taari K, Tammela T, Auvinen A, Murtola T
Prostate
. 2022 Nov;
83(3):246-258.
PMID: 36325820
Background: Diabetes has been associated with an increased risk of benign prostatic hyperplasia (BPH). However, the role of antidiabetic drugs as a BPH risk factor is unclear. The objective of...
7.
Kukko V, Kaipia A, Talala K, Taari K, Tammela T, Auvinen A, et al.
Prostate Cancer Prostatic Dis
. 2022 Sep;
27(1):73-80.
PMID: 36131010
Background: Allopurinol is gout medication that inhibits uric acid formation. Its possible anti-carcinogenic properties have been under research in past years. Studies based on Taiwanese registries showed that long term...
8.
Ola I, Talala K, Tammela T, Taari K, Murtola T, Kujala P, et al.
Int J Cancer
. 2022 Sep;
152(4):672-678.
PMID: 36056577
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low-risk disease with potential adverse effects. We evaluated PCa incidence among men with...
9.
Peltomaa A, Talala K, Taari K, Tammela T, Auvinen A, Murtola T
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740586
Statins have been associated with a decreased cancer mortality. However, cholesterol level as such may modify the risk of cancer death. To clarify the complex interplay between statins, cholesterol level,...
10.
Salminen J, Mehtola A, Talala K, Taari K, Makinen J, Peltola J, et al.
Br J Cancer
. 2022 May;
127(4):704-711.
PMID: 35505251
Background: Drugs with histone deacetylase inhibitory (HDACi) properties have shown to decrease prostate cancer (PCa) cell growth in vitro. Methods: A cohort of 9261 PCa cases from the Finnish Randomized...